Nevirapine (Synonyms: 奈韦拉平; BI-RG 587; NSC 641530; NVP)

目录号: HY-10570 纯度: 99.93%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Nevirapine (BI-RG 587) 是用于研究 HIV/AIDS 的 HIV-1 逆转录酶非核苷抑制剂，K_i 值为 270 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Nevirapine Chemical Structure

CAS No. : 129618-40-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥357	In-stock
5 mg	￥325	In-stock
10 mg	￥491	In-stock
25 mg	￥759	In-stock
50 mg	￥1100	In-stock
100 mg	￥1600	In-stock
200 mg	￥2600	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Nevirapine:

MCE 顾客使用本产品发表的 4 篇科研文献

Nevirapine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

查看所有亚型

HIV HIV-1 HIV-2

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM^[1].

IC₅₀ & Target

HIV-1

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
C8166	CC₅₀	> 749.1 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days	[PMID: 21194939]
C8166	IC₅₀	0.04 μM Compound: nevirapine (2)	Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain	10.1016/0960-894X(95)00257-T
CCRF-CEM	CC₅₀	> 100 μM Compound: NVP	Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]
CCRF-CEM	EC₅₀	> 10000 nM Compound: NVP	Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	> 10000 nM Compound: NVP	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	[PMID: 25418038]
CCRF-CEM	EC₅₀	> 10000 nM Compound: NVP	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	[PMID: 24769348]
CCRF-CEM	CC₅₀	> 10000 μM Compound: NVP	Cytotoxicity against human CEM cells by coulter counter analysis Cytotoxicity against human CEM cells by coulter counter analysis	[PMID: 21366296]
CCRF-CEM	CC₅₀	> 25 μM Compound: NVP	Cytotoxicity against human CEM cells after 3 days Cytotoxicity against human CEM cells after 3 days	10.1039/C3MD00036B
CCRF-CEM	CC₅₀	> 4 μM Compound: Nevirapine	Cytotoxicity against human CEM cells by MTT assay Cytotoxicity against human CEM cells by MTT assay	[PMID: 18242784]
CCRF-CEM	EC₅₀	> 50 μM Compound: nevirapine	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 18420310]
CCRF-CEM	EC₅₀	0.01 μM Compound: Nevirapine	Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	[PMID: 18242784]
CCRF-CEM	EC₅₀	0.024 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction of giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction of giant cell formation after 4 days by microscopic analysis	10.1039/C3MD00036B
CCRF-CEM	EC₅₀	0.12 μM Compound: nevirapine	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 18420310]
CCRF-CEM	EC₅₀	19.2 nM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	19.2 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	[PMID: 25418038]
CCRF-CEM	EC₅₀	19.2 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	[PMID: 24769348]
CEM-SS	EC₅₀	0.0015 μM Compound: nevirapine	Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 18222088]
CEM-SS	EC₅₀	0.015 μM Compound: nevirapine	Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay	[PMID: 17803290]
CEM-SS	EC₅₀	0.6 μM Compound: nevirapine	Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 19775161]
CEM-SS	EC₅₀	0.8 μM Compound: nevirapine	Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 19775161]
HEK-293T	IC₅₀	> 10 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	> 10 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	CC₅₀	> 10 μM Compound: nevirapine	Cytotoxicity against HEK293T cells after 48 hrs Cytotoxicity against HEK293T cells after 48 hrs	[PMID: 17035019]
HEK-293T	IC₅₀	> 10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	> 10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	> 10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	> 10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	CC₅₀	> 100 μM Compound: NVP	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEK-293T	IC₅₀	0.031 μM Compound: NVP	Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.031 μM Compound: NVP	Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	[PMID: 27484516]
HEK-293T	IC₅₀	0.05 μM Compound: Nevirapine	Antiviral activity against VSV-G protein pseudotyped HIV1 system in HEK293T cells assessed as reduction in p24 level after 48 hrs by ELISA Antiviral activity against VSV-G protein pseudotyped HIV1 system in HEK293T cells assessed as reduction in p24 level after 48 hrs by ELISA	[PMID: 25495797]
HEK-293T	EC₅₀	0.05 μM Compound: nevirapine	Antiviral activity against HIV in HEK293T cells after 48 hrs Antiviral activity against HIV in HEK293T cells after 48 hrs	[PMID: 17035019]
HEK-293T	IC₅₀	0.091 μM Compound: NVP	Inhibition of HIV reverse transcriptase transfected in HEK293T cells assessed as reduction in viral replication measured at 48 hrs postinfection by luciferase reporter based single-cycle non replicative phenotypic assay Inhibition of HIV reverse transcriptase transfected in HEK293T cells assessed as reduction in viral replication measured at 48 hrs postinfection by luciferase reporter based single-cycle non replicative phenotypic assay	[PMID: 27287366]
HEK-293T	IC₅₀	0.12 μM Compound: Nevirapine	Antiviral activity against HIV1 infected in HEK293T cells by p24 ELISA based phenotypic assay Antiviral activity against HIV1 infected in HEK293T cells by p24 ELISA based phenotypic assay	[PMID: 25176191]
HEK-293T	IC₅₀	16.1 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	16.1 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	IC₅₀	2.8 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	2.8 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	CC₅₀	23.72 μM Compound: Nevirapine	Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay	[PMID: 32004936]
HEK-293T	IC₅₀	5 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	5 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	5.48 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	5.48 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	66.7 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	66.7 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	CC₅₀	92.7 μM Compound: NVP	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30783503]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	> 2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	CC₅₀	> 4 μM Compound: Nevirapine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
HeLa	IC₅₀	118 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1868 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	294 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	304 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	409 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	53 nM Compound: nevirapine, NVP	Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	59 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	71 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	801 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	83 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	89 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HuT78	CC₅₀	> 14 μM Compound: Nevirapine	Cytotoxicity against human HUT78 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human HUT78 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 26613134]
HuT78	EC₅₀	0.26 μM Compound: Nevirapine	Antiviral activity against HIV1 3B persistently infected in HUT78 cells assessed as reduction of p24 production after 43 hrs by ELISA Antiviral activity against HIV1 3B persistently infected in HUT78 cells assessed as reduction of p24 production after 43 hrs by ELISA	[PMID: 26613134]
Jurkat	EC₅₀	< 0.2 μg/mL Compound: Nevirapine	Antiviral activity against HIV S056 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV S056 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	> 2 μg/mL Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV2 ROD infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	CC₅₀	> 2 μg/mL Compound: Nevirapine	Cytotoxicity against human Jurkat A72 cells by MTT assay Cytotoxicity against human Jurkat A72 cells by MTT assay	[PMID: 20377249]
Jurkat	EC₅₀	0.005 μg/mL Compound: Nevirapine	Antiviral activity against AZT-resistant HIV infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against AZT-resistant HIV infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.008 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV1 3B infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.008 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 NL4-3 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV1 NL4-3 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.012 μg/mL Compound: Nevirapine	Antiviral activity against HIV S07 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV S07 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.016 μg/mL Compound: Nevirapine	Antiviral activity against HIV S067 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV S067 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	IC₅₀	40 nM Compound: Nevirapine	Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay	[PMID: 21414776]
MOLT-3	CC₅₀	20.06 μg/mL Compound: NEV	Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay	[PMID: 21334901]
MRC5	IC₅₀	> 64 μM Compound: Nevirapine	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	[PMID: 25199582]
MRC5	IC₅₀	> 64 μM Compound: Nevirapine	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	[PMID: 25199582]
MT2	CC₅₀	> 10 μM Compound: nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 17918923]
MT2	CC₅₀	> 10 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 16298131]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT2 cells assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 33603971]
MT2	EC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay	[PMID: 35175760]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with wild-type HIV1 NL4-3 measured 48 hrs by MTT assay Cytotoxicity against human MT2 cells infected with wild-type HIV1 NL4-3 measured 48 hrs by MTT assay	[PMID: 31281023]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method	[PMID: 27485603]
MT2	CC₅₀	> 100 μM Compound: nev	Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay	[PMID: 25408842]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 23899617]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 22269110]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay	[PMID: 22081993]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20304641]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	[PMID: 20304641]
MT2	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	[PMID: 20304641]
MT2	EC₅₀	> 14.8 μM Compound: nevirapine	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 67N, 210W, 215Y, 184V, 103N mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 67N, 210W, 215Y, 184V, 103N mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	EC₅₀	> 14.8 μM Compound: nevirapine	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 74V, 184V, 210W, 215Y, ins SS, 98G mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 74V, 184V, 210W, 215Y, ins SS, 98G mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	EC₅₀	> 14.8 μM Compound: nevirapine	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase clone 7324-1 infected human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase clone 7324-1 infected human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	EC₅₀	> 3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase 6005MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase 6005MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	> 3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase 8605MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase 8605MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	> 3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	> 3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	0.053 μM Compound: 1	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	0.11 μM Compound: nev	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	[PMID: 23899617]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.11 μM Compound: nevirapine	Antiviral activity against HIV1 3B in human MT2 cells by MTT assay Antiviral activity against HIV1 3B in human MT2 cells by MTT assay	[PMID: 17918923]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	EC₅₀	0.12 μM Compound: Nevirapine	Antiviral activity against HIV1 3B in MT2 cells by MTT assay Antiviral activity against HIV1 3B in MT2 cells by MTT assay	[PMID: 16298131]
MT2	EC₅₀	0.25 μM Compound: Nevirapine	Antiviral activity against X4 tropic HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTT assay Antiviral activity against X4 tropic HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTT assay	[PMID: 25176328]
MT2	EC₅₀	0.29 μM Compound: nevirapine	Antiviral activity against wild type HIV1 3B in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against wild type HIV1 3B in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	CC₅₀	320 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells after 4 to 5 days by MTT assay Cytotoxicity against human MT2 cells after 4 to 5 days by MTT assay	[PMID: 25176328]
MT2	CC₅₀	96171 nM Compound: NVP	Cytotoxicity against human MT2 cells assessed as reduction in cell viability measured after 4 days by Trypan blue assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability measured after 4 days by Trypan blue assay	[PMID: 31893549]
MT4	CC₅₀	< 300 μM Compound: Nevirapine	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 8558522]
MT4	CC₅₀	> 0.015 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 28481112]
MT4	IC₅₀	> 0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	10.1007/s00044-012-0129-4
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	[PMID: 22283377]
MT4	IC₅₀	> 10 μM Compound: Nevirapine	Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	> 10 μM Compound: Nevirapine	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	> 10 μM Compound: Nevirapine	Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	> 10 μM Compound: NVP	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	CC₅₀	> 100 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	[PMID: 19775780]
MT4	CC₅₀	> 100 μM Compound: NVP	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	EC₅₀	> 14.4 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 25150090]
MT4	CC₅₀	> 14.4 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 25150090]
MT4	CC₅₀	> 14.9 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 23415090]
MT4	CC₅₀	> 14.99 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 23159806]
MT4	CC₅₀	> 14.99 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24631361]
MT4	CC₅₀	> 15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	> 15 μM Compound: Nevirapine, Viramune	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 21903401]
MT4	CC₅₀	> 15 μM Compound: Nevirapine, Viramune	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21903401]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35780636]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35073089]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 34403976]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against in human MT-4 cells after 5 days by MTT assay Cytotoxicity against in human MT-4 cells after 5 days by MTT assay	[PMID: 33851529]
MT4	CC₅₀	> 15 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31735575]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29534929]
MT4	CC₅₀	> 15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 28314598]
MT4	CC₅₀	> 15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28314514]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27750153]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	> 15 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	CC₅₀	> 15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 26613134]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	> 15 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 25127466]
MT4	CC₅₀	> 15 μM Compound: Nevirapine	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25127466]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25089812]
MT4	CC₅₀	> 15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	> 15 μM Compound: nevirapine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24680058]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24581546]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24239481]
MT4	CC₅₀	> 15 μM Compound: NEV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24134904]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24119448]
MT4	EC₅₀	> 15 μM Compound: NEV	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	> 15 μM Compound: NEV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	> 15 μM Compound: NVP	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	> 15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 35649164]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34432448]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock infected human MT4 cells by MTT assay Cytotoxicity against mock infected human MT4 cells by MTT assay	[PMID: 34197708]
MT4	EC₅₀	> 15 μM Compound: nevirapine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	> 15 μM Compound: 1, NVP	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23084898]
MT4	EC₅₀	> 15 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	CC₅₀	> 15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 22883027]
MT4	CC₅₀	> 15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days Cytotoxicity against human MT4 cells after 5 days	[PMID: 19616956]
MT4	EC₅₀	> 15.02 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	> 15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	CC₅₀	> 15.02 μM Compound: NEV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	> 15.02 μM Compound: NEV	Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	> 15.02 μM Compound: NEV	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20307984]
MT4	CC₅₀	> 15.02 μM Compound: NEV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20307984]
MT4	CC₅₀	> 15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 33979774]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33567378]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32712537]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32197813]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29635166]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29559197]
MT4	CC₅₀	> 15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29291935]
MT4	CC₅₀	> 15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28559060]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 28254696]
MT4	CC₅₀	> 15.02 μM Compound: Nevirapine	Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 26385446]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	[PMID: 24602795]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	> 15.02 μM Compound: NVP	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	> 15.02 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	> 15.02 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	[PMID: 21683601]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	[PMID: 19628308]
MT4	CC₅₀	> 15.02 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	[PMID: 35640327]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay	10.1007/s00044-009-9220-x
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 29670703]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 28987601]
MT4	CC₅₀	> 15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells measured by MTT assay Cytotoxicity against human MT4 cells measured by MTT assay	[PMID: 22037050]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19643613]
MT4	CC₅₀	> 15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	CC₅₀	> 15.021 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24952305]
MT4	CC₅₀	> 15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 31421633]
MT4	CC₅₀	> 15.03 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	[PMID: 34090079]
MT4	CC₅₀	> 15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31714780]
MT4	CC₅₀	> 15.03 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	CC₅₀	> 15020 nM Compound: NVP	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	> 15020 nM Compound: NVP	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	CC₅₀	> 15021 nM Compound: 1, NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 26276435]
MT4	EC₅₀	> 15021 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	> 15021 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	> 15037 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	> 15037 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	> 15037 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	> 18 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	CC₅₀	> 18776 nM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	[PMID: 22712652]
MT4	CC₅₀	> 18776 nM Compound: NVP	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 32883642]
MT4	CC₅₀	> 18776 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 28628334]
MT4	CC₅₀	> 18776 nM Compound: NVP	Cytotoxic activity against human MT4 cells by MTT assay Cytotoxic activity against human MT4 cells by MTT assay	[PMID: 25418038]
MT4	CC₅₀	> 18776 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24769348]
MT4	EC₅₀	> 18850 nM Compound: NVP	Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	> 18916 nM Compound: NVP	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	ED₅₀	> 2 μM Compound: NVP	Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	CC₅₀	> 20 μg/mL Compound: BI-RG-587	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	EC₅₀	> 20 μM Compound: NVP	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	[PMID: 24805780]
MT4	EC₅₀	> 20 μM Compound: NVP	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	> 20 μM Compound: NVP	Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	> 20 μM Compound: NVP	Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	CC₅₀	> 200 μM Compound: nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17869386]
MT4	CC₅₀	> 200 μM Compound: nevirapine	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	> 200 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18952324]
MT4	CC₅₀	> 200 μM Compound: Nevirapine	50% cytotoxic concentration against mock-infected MT-4 cells using MTT method 50% cytotoxic concentration against mock-infected MT-4 cells using MTT method	[PMID: 10794705]
MT4	CC₅₀	> 200 μM Compound: nevirapine	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(97)00340-5
MT4	CC₅₀	> 200 μM Compound: Nevirapine	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	ED₅₀	> 20000 nM Compound: NVP	Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay	[PMID: 17803291]
MT4	EC₅₀	> 30 μM Compound: Nevirapine	Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	> 30 μM Compound: Nevirapine	Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method	[PMID: 15634015]
MT4	CC₅₀	> 300 μM Compound: nevirapine	Dose required to reduce the viability of mock-infected cells by 50% Dose required to reduce the viability of mock-infected cells by 50%	[PMID: 9154967]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	> 3756 nM Compound: NVP	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	CC₅₀	> 376 μM Compound: Nevirapine	Compound dose required to reduce the viability of mock-infected cells by 50% Compound dose required to reduce the viability of mock-infected cells by 50%	[PMID: 7650679]
MT4	CC₅₀	> 4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	> 4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	CC₅₀	> 4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	> 4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	CC₅₀	> 4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	CC₅₀	> 4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 5 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 5 days by MTT assay	10.1007/s00044-012-0129-4
MT4	IC₅₀	> 4 μg/mL Compound: Nevirapine	Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	CC₅₀	> 4 μg/mL Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27647368]
MT4	CC₅₀	> 4 μg/mL Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	CC₅₀	> 4 μg/mL Compound: BOE, BIRG587	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	> 4 μg/mL Compound: BOE, BIRG587	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	> 4 μg/mL Compound: nevirapine	Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	CC₅₀	> 4 μg/mL Compound: nevirapine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 19091580]
MT4	EC₅₀	> 4 μg/mL Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	CC₅₀	> 4 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 30318436]
MT4	CC₅₀	> 4 μM Compound: NVP, Viramune	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 23357038]
MT4	EC₅₀	> 4 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	CC₅₀	> 4.6 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	> 4000 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 29353724]
MT4	CC₅₀	> 5 μg/mL Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	EC₅₀	> 5 μM Compound: NEV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24134904]
MT4	CC₅₀	> 50 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18242784]
MT4	CC₅₀	> 7 μM Compound: NVP, nevirapine	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17910429]
MT4	CC₅₀	> 7 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method	[PMID: 24933420]
MT4	EC₅₀	> 7 μM Compound: NVP	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	> 7 μM Compound: NVP	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	CC₅₀	> 7 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18630898]
MT4	EC₅₀	> 7 μM Compound: NVP	Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	> 7 μM Compound: NVP	Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	> 7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	> 7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	CC₅₀	> 7.5 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19140683]
MT4	EC₅₀	> 7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	> 7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	CC₅₀	> 7.5 μM Compound: Nevirapine	Cytotoxicity against MT4 cells by MTT assay Cytotoxicity against MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	> 7.5 μM Compound: NVP	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	> 7.5 μM Compound: NVP	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	CC₅₀	> 7.5 μM Compound: NVP	Cytotoxicity against MT4 cells by MTT method Cytotoxicity against MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	> 7.58 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	> 7000 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30525601]
MT4	EC₅₀	> 7500 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	> 7500 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	> 7510 nM Compound: NVP	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	> 7510 nM Compound: NVP	Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	CC₅₀	> 80 μM Compound: BI-RG-587	Cytotoxic concentration required to reduce MT-4 cell viability by 50% Cytotoxic concentration required to reduce MT-4 cell viability by 50%	[PMID: 1501224]
MT4	EC₅₀	> 9.5 μM Compound: Nevirapine	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	CC₅₀	> 9.5 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 33340914]
MT4	CC₅₀	> 9.51 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32200201]
MT4	EC₅₀	≥ 11 μM Compound: NVP	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	≥ 15 μM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	≥ 15 μM Compound: NEV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	≥ 15.02 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay	[PMID: 27501911]
MT4	EC₅₀	≥ 2.02 μg/mL Compound: Nevirapine	Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	≥ 7.59 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	≥ 7.6 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	≥ 7.6 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	≥ 7.6 μM Compound: NVP	Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	≥ 7585 nM Compound: 1, NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	EC₅₀	≥ 7590 nM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	≥ 9.8 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	IC₅₀	0.01 μM Compound: nevirapine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	EC₅₀	0.01 μM Compound: nevirapine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	0.023 μg/mL Compound: nevirapine	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	EC₅₀	0.027 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	IC₅₀	0.03 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	EC₅₀	0.03 μM Compound: nevirapine	Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	EC₅₀	0.03 μM Compound: Nevirapine	Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method. Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.	[PMID: 9767646]
MT4	IC₅₀	0.032 μM Compound: Nevirapine	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	ED₅₀	0.04 μM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	EC₅₀	0.048 μM Compound: NVP, Viramune	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 23357038]
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	IC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	0.05 μg/mL Compound: BOE, BIRG587	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.05 μM Compound: Nevirapine	Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	[PMID: 18242784]
MT4	EC₅₀	0.052 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.052 μM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.053 μM Compound: nevirapine	Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18222088]
MT4	EC₅₀	0.053 μM Compound: nevirapine	Antiviral activity against HIV1 3B in human MT4 cells by XTT assay Antiviral activity against HIV1 3B in human MT4 cells by XTT assay	[PMID: 17803290]
MT4	EC₅₀	0.06 μM Compound: NVP	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.068 μM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	0.068 μM Compound: NVP	Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	[PMID: 22283377]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days	[PMID: 20097079]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days	[PMID: 19616956]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days	[PMID: 18585918]
MT4	IC₅₀	0.075 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	EC₅₀	0.075 μM Compound: Nevirapine, Viramune	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 21903401]
MT4	EC₅₀	0.075 μM Compound: NEV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	0.08 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.08 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	0.084 μM Compound: NVP	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.09 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.09 μM Compound: 1, NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.09 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.09 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.097 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.1 μM Compound: Nevirapine	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 3 to 4 days by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 3 to 4 days by MTT assay	[PMID: 25970729]
MT4	IC₅₀	0.101 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	EC₅₀	0.101 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay	[PMID: 24119448]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.113 μM Compound: NEV	Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24134904]
MT4	EC₅₀	0.12 μM Compound: NVP	Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	ED₅₀	0.12 μM Compound: Nevirapine	Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	EC₅₀	0.128 μM Compound: BI-RG-587	Concentration required to inhibit HIV-1 induced cytopathicity in MT-4 cells by 50% Concentration required to inhibit HIV-1 induced cytopathicity in MT-4 cells by 50%	[PMID: 1501224]
MT4	EC₅₀	0.13 μM Compound: NVP	Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	0.13 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by microtiter plate analysis Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by microtiter plate analysis	[PMID: 21093117]
MT4	EC₅₀	0.15 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay	[PMID: 25089812]
MT4	ED₅₀	0.15 μM Compound: Nevirapine	Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	EC₅₀	0.15 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.15 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.17 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 24239481]
MT4	EC₅₀	0.17 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 24631361]
MT4	EC₅₀	0.17 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.18 μM Compound: Nevirapine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 32197813]
MT4	EC₅₀	0.18 μM Compound: Nevirapine	Antiviral activity against HIV1 3B acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 25127466]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV1 3B harboring wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24581546]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 25150090]
MT4	EC₅₀	0.19 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.19 μM Compound: Nevirapine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 24457088]
MT4	EC₅₀	0.199 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.2 μM Compound: NEV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20307984]
MT4	EC₅₀	0.2 μM Compound: NVP	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay	10.1007/s00044-009-9220-x
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	[PMID: 19628308]
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 19643613]
MT4	EC₅₀	0.21 μM Compound: NEV	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.21 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.21 μM Compound: NVP	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 21683601]
MT4	EC₅₀	0.22 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.23 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.23 μM Compound: NVP	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.244 μM Compound: NVP	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	IC₅₀	0.25 μM Compound: nevirapine	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	EC₅₀	0.25 μM Compound: Nevirapine	Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by MTT assay	[PMID: 18952324]
MT4	IC₅₀	0.25 μM Compound: nevirapine	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay	[PMID: 17869386]
MT4	IC₅₀	0.25 μM Compound: Nevirapine	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	EC₅₀	0.26 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.28 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.28 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	0.29 μM Compound: NVP	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.3 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.3 μM Compound: NVP	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.3 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	0.3 μM Compound: Nevirapine	Compound dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathicity using MTT method Compound dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathicity using MTT method	[PMID: 10698447]
MT4	EC₅₀	0.31 μM Compound: Nevirapine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.31 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.3117 μM Compound: Nevirapine	Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.35 μM Compound: Nevirapine	Effective concentration against HIV-1 induced cytopathicity in MT-4 cells using MTT method Effective concentration against HIV-1 induced cytopathicity in MT-4 cells using MTT method	[PMID: 10794705]
MT4	EC₅₀	0.35 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.37 μM Compound: Nevirapine	Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	0.38 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.46 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	ED₅₀	0.62 μM Compound: Nevirapine	Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	ED₅₀	0.68 μM Compound: NVP	Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	EC₅₀	0.83 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.87 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	IC₅₀	0.9 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	EC₅₀	0.901 μM Compound: NVP	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	IC₅₀	1 x 10⁴ nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1 x 10⁵ nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1 x 10⁵ nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	1 μM Compound: NVP	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	1.8 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	1.92 μM Compound: NVP	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	1.97 μM Compound: NVP	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	IC₅₀	10 μM Compound: Nevirapine	Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	EC₅₀	102 nM Compound: NEV	Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	11 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	11.2 μM Compound: NVP	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	112.4 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	112.4 nM Compound: NVP	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	130 nM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	131.4 nM Compound: NVP	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	1316 nM Compound: NEV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	IC₅₀	135 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	ED₅₀	14000 nM Compound: NVP	Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay	[PMID: 17803291]
MT4	EC₅₀	14505 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	IC₅₀	1452 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	15 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	CC₅₀	15 μM Compound: 1, NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	CC₅₀	15 μM Compound: Nevirapine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 18083556]
MT4	CC₅₀	15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 17803290]
MT4	CC₅₀	15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35679690]
MT4	CC₅₀	15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	1502 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	15021 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	156 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days by spectrophotometry Cytotoxicity against human MT4 cells after 5 days by spectrophotometry	[PMID: 21093117]
MT4	EC₅₀	162 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	IC₅₀	163 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	195 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	1980 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	2.5 μM Compound: NVP	Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 24239481]
MT4	EC₅₀	2.9 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay	[PMID: 25089812]
MT4	EC₅₀	200.4 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	2030 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	209 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	2107 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	ED₅₀	22 μM Compound: Nevirapine	Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	EC₅₀	250 nM Compound: NVP	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	2697 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	271 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	3 μM Compound: NVP	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	3.49 μM Compound: Nevirapine	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	3.5 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24581546]
MT4	EC₅₀	3.5 μM Compound: NEV	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	3.9 μM Compound: Nevirapine	Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	3.9 μM Compound: Nevirapine	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	3.9 μM Compound: NVP	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	IC₅₀	31.6 nM Compound: NVP	Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	312 nM Compound: 1, NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	EC₅₀	312 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	IC₅₀	316 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	316 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	CC₅₀	31631 nM Compound: 14, nevirapine	Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay	[PMID: 17223230]
MT4	CC₅₀	325.13 μM Compound: NVP	Cytotoxicity against human MT4 cells after 3 days by XTT assay Cytotoxicity against human MT4 cells after 3 days by XTT assay	[PMID: 23540737]
MT4	CC₅₀	325.13 μM Compound: NVP	Cytotoxicity against human MT4 cells after 3 days by XTT assay Cytotoxicity against human MT4 cells after 3 days by XTT assay	[PMID: 22283377]
MT4	EC₅₀	33.3 nM Compound: 14, nevirapine	Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	3532 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	CC₅₀	4 μg/mL Compound: Nevirapine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	EC₅₀	4 μM Compound: NVP	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	4.09 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	4.96 μM Compound: NVP	Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	IC₅₀	44 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	5.12 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	5.12 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	5.6 μM Compound: NVP	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	5.6 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	ED₅₀	50 nM Compound: NVP	Antiviral activity against HIV1 3B in MT4 cells by MTT assay Antiviral activity against HIV1 3B in MT4 cells by MTT assay	[PMID: 17803291]
MT4	IC₅₀	5012 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	509 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	51 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	5392 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5910 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	6.21 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	IC₅₀	6.3 μM Compound: Nevirapine	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	EC₅₀	6.78 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	60 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	60 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	6100 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	6121 nM Compound: NVP	Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	IC₅₀	6310 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	6729 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	683 μM Compound: Nevirapine	Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method. Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.	[PMID: 9767646]
MT4	CC₅₀	683 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20638854]
MT4	CC₅₀	683 μM Compound: nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	EC₅₀	7 μM Compound: NVP	Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	7.17 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	7.25 μM Compound: NVP	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	7.64 μM Compound: NVP	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	7078 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	CC₅₀	7500 nM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22428851]
MT4	CC₅₀	7510 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 21438533]
MT4	IC₅₀	7943 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	EC₅₀	827 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	9.61 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	9.9 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	90.1 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
PBMC	CC₅₀	> 100 μM Compound: NVP	Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]
PBMC	IC₅₀	0.04 μM Compound: NVP	Antiviral activity against HIV-1 Bal infected in human PBMC by MTS assay Antiviral activity against HIV-1 Bal infected in human PBMC by MTS assay	[PMID: 28442262]
PBMC	CC₅₀	1003 μM Compound: Nevirapine	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31557609]
PBMC	CC₅₀	40.88 μg/mL Compound: NEV	Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay	[PMID: 21334901]
TZM	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human TZM-bl cells assessed as reduction of cell viability after 48 hrs Cytotoxicity against human TZM-bl cells assessed as reduction of cell viability after 48 hrs	[PMID: 27108399]
TZM	CC₅₀	> 15000 nM Compound: 1; NVP	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	[PMID: 33340914]
TZM	CC₅₀	> 50 μM Compound: Nevirapine	Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay	[PMID: 25199582]
TZM	CC₅₀	204.003 μM Compound: NVP	Cytotoxicity against human TZM-bl cells after 3 days by XTT assay Cytotoxicity against human TZM-bl cells after 3 days by XTT assay	[PMID: 25468035]
TZM	CC₅₀	76.13 μg/mL Compound: Nevirapine	Cytotoxicity in human TZM-bl cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human TZM-bl cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21982685]
TZM	CC₅₀	76.13 μM Compound: NVP	Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay	[PMID: 24794742]
U2OS	CC₅₀	> 100 μM Compound: Nevirapine	Cytotoxicity against human U2OS cells assessed as reduction of cell viability after 48 hrs Cytotoxicity against human U2OS cells assessed as reduction of cell viability after 48 hrs	[PMID: 27108399]
U2OS	IC₅₀	0.42 μM Compound: Nevirapine	Antiviral activity against HIV1 virus-like particles harboring wild type reverse transcriptase infected in human U2OS cells after 24 hrs by Renilla luciferase assay Antiviral activity against HIV1 virus-like particles harboring wild type reverse transcriptase infected in human U2OS cells after 24 hrs by Renilla luciferase assay	[PMID: 27108399]
Vero	IC₅₀	> 100 μg/mL Compound: Nevirapine	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27105027]
Vero	CC₅₀	> 100 μM Compound: NVP	Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]

体外研究
(In Vitro)

Nevirapine itself is an inhibitor of only CYP3A4 at concentrations that are well above those of therapeutic relevance (K_i=270 μM)^[1]. Nevirapine has been used as a re-differentiation agent to treat cancers in several human cancer models. At all doses (100, 200, 350, 500 μM) tested, nevirapine significantly inhibits cell proliferation after 48 h treatment. At high dose (500 μM), nevirapine significantly increases the percentage of apoptotic cells compared with control^[2]. Nevirapine is a potent and selective inhibitor (IC₅₀=10-100 nM) of the replication of a wide variety of HIV-1 strains in several cellular assays^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Nevirapine is available for use in combination with nucleoside HIV-1 reverse transcriptase inhibitors (e.g., zidovudine, didanosine, etc.). Nevirapine has received FDA approval for use in combination with HIV-1 protease inhibitors (e.g., saquinavir, ritonavir, indinavir, etc.). In humans, nevirapine is eliminated primarily in the urine as glucuronide conjugates of 2-, 3-, 8-, and 12-hydroxynevirapine^[1]. Nevirapine is completely absorbed in both sexes of mouse, rat, rabbit, monkey, and chimpanzee. Nevirapine is extensively metabolized in both sexes of all animal species studied^[4]. Nevirapine (9 mg/kg, 18 mg/kg and 36 mg/kg) shows significant reduction in ulcer severity score and ulcer index as compared to the control^[5]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

266.30

Formula

C₁₅H₁₄N₄O

CAS 号

129618-40-2

性状

固体

颜色

White to off-white

中文名称

奈韦拉平；萘维拉平；那韦拉平；奈韦那平；萘韦拉平

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 14.29 mg/mL (53.66 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7552 mL	18.7758 mL	37.5516 mL
5 mM	0.7510 mL	3.7552 mL	7.5103 mL
10 mM	0.3755 mL	1.8776 mL	3.7552 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.43 mg/mL (5.37 mM); 澄清溶液

此方案可获得 ≥ 1.43 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 1.43 mg/mL (5.37 mM); 澄清溶液

此方案可获得 ≥ 1.43 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 14.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.93%

选择批次：

Data Sheet (633 KB) SDS (394 KB)

COA (205 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Erickson DA, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitornevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95. [Content Brief]

[2]. Dong JJ, et al. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013 May 6;370(1-2):113-8. [Content Brief]

[3]. Merluzzi VJ, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411-3. [Content Brief]

[4]. Riska PS, et al. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab Dispos. 1999 Dec;27(12):1434-47. [Content Brief]

[5]. Onasanwo SA, et al. Evaluation of anti-ulcerogenic and ulcer-healing activities of nevirapine in rats. Afr J Med Med Sci. 2015 Sep;44(3):251-9. [Content Brief]

Cell Assay ^[2]	FRO cells are seeded into 96-well culture plates at 10,000 cells/well. Cells are treated with different doses of nevirapine (0, 100, 200, 350 and 500 μM) for 48 h. MTT dye (5 mg/mL) is added to each well for additional 4 h, and the reaction is then stopped by the addition of DMSO. Optical density is measured at 490 nm on a multi-well plate reader^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Rats: Nevirapine and [¹⁴C] Nevirapine are dissolved together in absolute ethanol and methylene chloride (1:1, v/v) with mild heating. The concentration of drug in suspension is 2 mg/mL (20 mg/kg, 26 μCi) for oral dosing to rats and 6.7 mg/mL (20.3 mg/kg, 10 μCi males, 8.9 μCi females) for intraduodenal administration to rats before bile collection. The i.v. dose is administered to rats (1.1 mg/kg, 20 μCi) as a solution in 20% ethanol/80% saline^[4]. Mice: Nevirapine and [¹⁴C] Nevirapine are dissolved together in absolute ethanol and methylene chloride (1:1, v/v) with mild heating. The concentration of drug in suspension is 2 mg/mL (20 mg/kg, 2.5 μCi) with a specific activity of 5.55 μCi/mg for oral dosing to mice^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Erickson DA, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitornevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95. [Content Brief] [2]. Dong JJ, et al. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013 May 6;370(1-2):113-8. [Content Brief] [3]. Merluzzi VJ, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411-3. [Content Brief] [4]. Riska PS, et al. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab Dispos. 1999 Dec;27(12):1434-47. [Content Brief] [5]. Onasanwo SA, et al. Evaluation of anti-ulcerogenic and ulcer-healing activities of nevirapine in rats. Afr J Med Med Sci. 2015 Sep;44(3):251-9. [Content Brief]

Nevirapine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7552 mL	18.7758 mL	37.5516 mL	93.8791 mL
	5 mM	0.7510 mL	3.7552 mL	7.5103 mL	18.7758 mL
	10 mM	0.3755 mL	1.8776 mL	3.7552 mL	9.3879 mL
	15 mM	0.2503 mL	1.2517 mL	2.5034 mL	6.2586 mL
	20 mM	0.1878 mL	0.9388 mL	1.8776 mL	4.6940 mL
	25 mM	0.1502 mL	0.7510 mL	1.5021 mL	3.7552 mL
	30 mM	0.1252 mL	0.6259 mL	1.2517 mL	3.1293 mL
	40 mM	0.0939 mL	0.4694 mL	0.9388 mL	2.3470 mL
	50 mM	0.0751 mL	0.3755 mL	0.7510 mL	1.8776 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Nevirapine (Synonyms: 奈韦拉平; BI-RG 587; NSC 641530; NVP)

Customer Review

Other Forms of Nevirapine:

MCE 顾客使用本产品发表的 4 篇科研文献

Nevirapine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Nevirapine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Nevirapine (Synonyms: 奈韦拉平; BI-RG 587; NSC 641530; NVP)

Customer Review

Other Forms of Nevirapine:

Nevirapine 相关抗体

MCE 顾客使用本产品发表的 4 篇科研文献

Nevirapine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Nevirapine 相关抗体:

摩尔计算器

稀释计算器

Nevirapine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z